Discussion in 'Other Health News and Research' started by BurnA, Sep 2, 2017.
Wasn't it Mario Capecchi at the Stanford Symposium who emphasized the importance of developing a mouse model for ME/CFS?
What happens long term, the short term memory may be great to knock out (with Rituximab?) but if there is a long term we would need to fix it because it usually takes years to get diagnosed with ME/CFS or presumably most autoimmune diseases.
Could this even explain why only 60% remission is achieved in Rituximab trials?
Just as I saw your post I was reading about the various scientific theories as to why autoimmune disease are more prevalent in women than men. I was unaware of many of these theories. Interesting.
There doesn't seem to be any substantial evidence of this in humans though - each autoimmune disease seems to have it's own specific autoantibodies, rather than some generalised lack of B-Cell tolerance.
This is the first study I have seen with this kind of specific claim. Its interesting. Its also a long way to go before we have clinical application.
It might explain the Rituximab successes and failures. Might. So might other things. In ten or twenty years people will look back and ask why the answer is not obvious. We are mired in both a sea of uncertainty and quagmires of unfounded certainty. Or to put it another way, a lack of research and too much dogma.
In less than two months we might have early word, however brief, on how Rituximab is doing.
@Jonathan Edwards, it'd be interesting to know if you have an opinion on this.
You can also try a Google Site Search
Separate names with a comma.